How do you approach later-line sequencing in cGvHD in your clinical practice?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
How do you approach later-line sequencing in cGvHD in your clinical practice?
-
ナレーター：
-
著者：
The GvHD Hub spoke with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, How do you approach later-line sequencing in cGvHD in your clinical practice?
Cutler discusses his approach to selecting second-line and subsequent therapies for patients with cGvHD. He explains that, in his practice, treatment selection is guided primarily by FDA approval status and toxicity profiles, while organ involvement plays a more limited, context-dependent role. He highlights patient comorbidities and practical considerations, such as route of administration and dosing frequency, as additional factors that may influence therapy selection.
This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.